DeCell Technologies is an emerging biomedical device manufacturer that is developing advanced tissue products for use in wound healing and surgical reconstructions. The company’s patent-pending, innovative technology processes donated human tissue to remove cellular components (i.e., source of rejection) while leaving the structural matrix of the tissue intact. During processing, potential bacteria and viruses are also deactivated and removed, resulting in a sterile, safe and effective biological scaffold that promotes tissue regeneration when implanted into a patient.
Unique automated manufacturing equipment developed in-house ensures quality and consistency of DeCell’s product at a low cost.
At present, DeCell is addressing the unmet need of treating chronic foot ulcers in diabetic patients. However, the platform technology can also provide healing solutions for other chronic wounds, burn victims, and surgical reconstructions.